<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-76862</identifier>
<setSpec>0214-3429</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">In vitro activities of posaconazole, fluconazole, itraconazole, ketoconazole and voriconazole against Candida glabrata</dc:title>
<dc:description xml:lang="en">This study has been conducted to asses the in vitro activityof the novel triazole antifungal agent posaconazoleagainst 123 clinically important isolates of yeasts. Susceptibilitywas tested using the Sensititre YeastOne microdilutioncommercial method. Minimun inhibitory concentrations(MICs) were determined at the recommendedendpoints and time intervals. The activity of posaconazole against Candida glabrata was compared with those offluconazole, itraconazole, ketoconazole and voriconazole.The most susceptible species to posaconazole were C. albicans,C. parapsilosis, C. tropicalis and C. dubliniensis. Candidaglabrata was the least susceptible. The percentage ofstrains with MIC for posaconazole ¡Ý 1 mg/L was 9%, allof them were C. glabrata. The species with MIC for itraconazole¡Ý 0.5 mg/L were 36% (41 C. glabrata, 1 C. krusei,1 C. guilliermondii, 1 C. ciferrii). Candida glabrata strainsresistant to fluconazole, ketoconazole and voriconazole were8%, 4% and 4%, respectively. Posaconazole exhibited goodactivity to the majority of Candida species. However, it wassimilar to itraconazole and less active than ketoconazoleand voriconazole against C. glabrata (AU)</dc:description>
<dc:creator>Cañadas, J</dc:creator>
<dc:creator>Garc¨ªa-Tapia, A</dc:creator>
<dc:creator>Mar¨ªn, P</dc:creator>
<dc:creator>Rodr¨ªguez, M. J</dc:creator>
<dc:creator>Garc¨ªa-Martos, P</dc:creator>
<dc:creator>Blanco, M. T</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El prop¨®sito del presente trabajo ha sido determinar la actividadin vitro del nuevo antif¨²ngico triazol posaconazol frentea 123 aislamientos de levaduras de inter¨¦s cl¨ªnico. La susceptibilidadfue testada mediante el m¨¦todo comercial de microdiluci¨®nSensititre YeastOne. Las concentraciones m¨ªnimasinhibitorias (CMI) fueron establecidas de acuerdo con los criteriosrecomendados. Los resultados de la actividad de posaconazolfrente a Candida glabrata fueron comparados con losde fluconazol, itraconazol, ketoconazol y voriconazol. Las especiesm¨¢s sensibles a posaconazol fueron C. albicans, C. parapsilosis,C. tropicalis y C. dubliniensis. La especie menos sensiblefue C. glabrata. El porcentaje de cepas con CMI ¡Ý 1 mg/lpara posaconazol fue del 9%, todas ellas C. glabrata. Las especiescon CMI ¡Ý 0,5 mg/l para itraconazol supusieron un 36%(41 C. glabrata, 1 C. krusei, 1 C. guilliermondii, 1 C. ciferrii). Lascepas de C. glabrata resistentes a fluconazol, ketoconazol y voriconazolfueron el 8%, 4%y 4%, respectivamente. Posaconazolmuestra una buena activitad frente a la mayor¨ªa de las especiesde Candida; sin embargo, frente a C. glabrata es similar aitraconazol y menos activo que ketoconazol y voriconazol (AU)</dc:description>
<dc:source>Rev Esp Quimioter;22(3): 139-143, sep. 2009. tab</dc:source>
<dc:identifier>ibc-76862</dc:identifier>
<dc:title xml:lang="es">Actividad in vitro de posaconazol,fluconazol, itraconazol, ketoconazoly voriconazol frente a Candida glabrata</dc:title>
<dc:subject>^d943^s22078</dc:subject>
<dc:subject>^d36630^s22021</dc:subject>
<dc:subject>^d36324</dc:subject>
<dc:subject>^d24244</dc:subject>
<dc:subject>^d22780</dc:subject>
<dc:type>article</dc:type>
<dc:date>200909</dc:date>
</metadata>
</record>
</ibecs-document>
